Important Announcements

Nondiscrimination Policy Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To read our full Nondiscrimination Statement, click here.

MULTISTEM

Select your language:

MULTISTEM: Double-blind, Randomized, Placebo-controlled Phase 2 Safety and Efficacy Trial of MultiStem in Adults with Ischemic Stroke

Sponsor: Athersys

Investigators: Viken Babikian MD (principal), Jose Romero MD, Thanh Nguyen MD, Carlos Kase MD

Summary

Stem cells are the 'master cells' of the body from which other cells, tissues, organs, and bones are created. The two types of human stem cells are 'embryonic stem cells' that are created during the very early formation of a baby and 'adult stem cells' that are found in the tissues of all adults. MultiStem is an adult stem call product made up of living cells that came from one adult donor's bone marrow and his similar features to other blood products. This donor is anonymous, meaning that the donor's identity is unknown to you, the study doctor, or study staff. This donor was medically tested to ensure that he or she was healthy and did not have medical conditions that could be passed to you.

Purpose

A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.

Results pending